Form 4: Rhythm Pharmaceuticals Director Stuart Arbuckle Reports Full Liquidation of Stock Holdings Following RSU Vesting

Rhythm Pharmaceuticals, Inc. Director Stuart A. Arbuckle reported the vesting of 4,000 restricted stock units and the subsequent disposition of 7,000 common shares, resulting in zero beneficial ownership.

Summary

• Stuart A. Arbuckle, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), reported a transaction on June 18, 2025.
• On this date, 4,000 Restricted Stock Units (RSUs) held by Mr. Arbuckle fully vested, converting into 4,000 shares of RYTM common stock.
• The RSUs had an exercise price of $0.00, indicating they were contingent rights to receive shares upon vesting.
• Concurrently, Mr. Arbuckle disposed of 7,000 shares of RYTM common stock.
• Following these transactions, Mr. Arbuckle's beneficial ownership of both non-derivative and derivative securities in Rhythm Pharmaceuticals, Inc. is reported as 0.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the net disposition of shares by a director, which can be interpreted as a lack of confidence, despite the positive event of RSU vesting for the individual.

Positives

• The vesting of 4,000 Restricted Stock Units represents a successful compensation event for Director Stuart A. Arbuckle.

Negatives

• Director Stuart A. Arbuckle disposed of 7,000 shares of common stock, which included the 4,000 shares acquired from RSU vesting and an additional 3,000 shares previously held, resulting in a net reduction of his holdings to zero beneficial ownership.
• A net disposition of shares by a director can be perceived negatively by the market, potentially signaling a lack of confidence or a move to liquidate holdings.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider transactions are common occurrences in publicly traded companies, reflecting individual compensation events or personal financial planning.

Stakeholder Impact

• Shareholders may view the net disposition of shares by a director as a negative signal, potentially influencing investor sentiment and the company's stock price.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Stuart Arbuckle, Director, SEC Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Equity Disposition